Immediate Impact
6 from Science/Nature 65 standout
Citing Papers
Lorlatinib Versus Crizotinib in Patients With Advanced ALK -Positive Non–Small Cell Lung Cancer: 5-Year Outcomes From the Phase III CROWN Study
2024 Standout
Causes of death among people living with metastatic cancer
2024 Standout
Works of Frédérique Nowak being referenced
Crizotinib in patients with advanced ROS1-rearranged non-small cell lung cancer (NSCLC). Preliminary results of the ACSé phase II trial.
2015
Biomarkers (BM) France: Results of routine EGFR, HER2, KRAS, BRAF, PI3KCA mutations detection and EML4-ALK gene fusion assessment on the first 10,000 non-small cell lung cancer (NSCLC) patients (pts).
2013
Author Peers
| Author | Last Decade | Papers | Cites | |||
|---|---|---|---|---|---|---|
| Frédérique Nowak | 177 | 183 | 127 | 22 | 342 | |
| Marco Brugia | 208 | 122 | 95 | 30 | 334 | |
| T. Facchini | 290 | 86 | 123 | 22 | 386 | |
| Thomas Ferguson | 219 | 124 | 170 | 18 | 355 | |
| Iris Faull | 191 | 145 | 257 | 22 | 351 | |
| Séverine Sarp | 191 | 75 | 105 | 18 | 387 | |
| Piera Gargiulo | 196 | 83 | 99 | 26 | 380 | |
| Brenda Ernst | 189 | 104 | 202 | 30 | 365 | |
| Stephanie A. Hamilton | 253 | 102 | 155 | 12 | 402 | |
| Erica Quaquarini | 219 | 148 | 88 | 32 | 357 | |
| Claudia Lefeuvre | 148 | 132 | 208 | 15 | 364 |
All Works
Loading papers...